

Catherine H. Schein, PhD Adjunct Professor Biochemistry and Molecular Biology Tackling Variability in RNA viruses

Dr. Schein is a medicinal biochemist with experience in soluble protein production in bacteria, interferon and cytokine mechanisms, catabolic reactions of ribonucleases and autophagy, databases of allergens and viruses (SDAP, Flavitrack), bacterial toxin inhibitors, protein structure and computational drug design. All of this experience contributes to the current research in her lab group on broad spectrum antigens for vaccines designed with physicochemical property (PCP)- consensus and motif recognition, and synthetic conformational epitope mimetics (constrained and click chemistry peptides and proteins).

Abstract: The recent SARS-CoV-2 (COVID-19) epidemic has highlighted how the high variability of RNA viruses can present major obstacles to designing effective vaccines, therapies and diagnostics. However, long before coronaviruses became an existential threat, it was recognized that circulating RNA viruses, including poliovirus, influenza, dengue, West Nile, chikungunya etc. are not stable, but mixtures of evolving sequences differing from one another at a few positions. We have developed and validated, in 4 different virus groups, a suite of programs to identify regions of PCP-motifs and PCP-consensus sequences, as well as alignment-free methods to cluster sequences based on property distance (PD-Graph).

EM EM mbining individual alphavirus EM Mosalkun CHIKV Mosalkun Mosalkun AllAV Stills Mosalkun Stills AllAV AllAV Stills Mosalkun Stills Mosalkun AllAV AllAV Stills Mosalkun Stills Mosalkun Stills Mosalkun	EVC _{con} , a PCP-consensus of VEEVcon, EEEVcon and CHIKVcon, generates neutralizing antibodies against all three viruses. Recombinant proteins VEEV _{con} , CHIKV _{con} , EM _{con} (consensus of EEEV and Madariaga) and EVC _{con} , shown in the property distance graph (PD, left) were injected into rabbits. Sera were tested for their recognition of purified PCP- consensus proteins in a dotspot assay (top right) and in a plaque neutralization (PRNT50/80) assay against 3 viruses. Note the individual strain consensus do not recognize (in dotspot) or neutralize each other well, but the EVC _{con} immunized serum									
Image: Construction of the co		ombining individual alpha	virue		otted s	우	Mo .			
VEV.os VEV.os	Surface EM.com		protein: III III III III III III							
EV Mosaiken Mosaiken EV Mosaiken EV <th< td=""><td>Highland East</td><td>CF- Consensus to reach Ex</td><td colspan="5"></td></th<>	Highland East	CF- Consensus to reach Ex								
EVCore Mosaikung M	Pittorgan Service format	\frown								
EVCore Simulation Periodes 5-8 MOSalkon Evc., etc.,	(VESV _{ccn} of 93 strains)				Peptides 1-4					
Mosaiken Munuer Munue	435.0					EM oon +				
Example of B SISE 0 CPUIC of C Periodice 5-3 Mosalkon AllAV Sise 0 Sise 0 Periodice 5-3 Mosalkon AllAV Sise 0 Sise 0 Test of C Mosalkon CHIKVcon Sise 0 Sise 0 Test of C VEEV CHIKVcon Sise 0 CHIKVcon Test of C VEEV CHIKVcon Sise 0 CHIKVcon Test of C VEEV CHIKVcon CHIKVcon CHIKVcon Test of C VCON CHIKVcon CHIKVcon CHIKVcon Test of C VCON CHIKVcon CHIKVcon CHIKVcon Test of C <td< td=""><td colspan="7"></td><td></td></td<>										
Mosalkon torme Mosalko				Peptides 5	-8			-		
AllAV _{ton} Server Ser	Cabasoo Mossodaulveoras Mossaik.con Roskitueer	Strains or VE	EVcon,CHIKV	Probleed						
CHIKK/cm of 154 straining Protein PRNT 50	AllAVcon		, EMcon	11001000						
CHIKK/cm of 154 straining Protein PRNT 50	Plants Tanka Macanon Dilyinginginging									
VEEV.on 2643 6453 4-20 4-20 4-20 VEEV.on 264 4-20 4-20 CHIIVCON 264 4-20 4-20 CHIIVCON 264 4-20 4-20 EV.con 26	СНИХУ									
CHIKVeon 20 <20 80 <20 20 <20 EMcon 20 <20	Everytates VEEV.con									
EMcon 20 <20 40 <20 640 320 EVCcon 40 <20 80 <20 160 20		\sim								
Mary V	9 Barradonat		EVCcon 40	<20	80	<20	160	20		
	Tiskerse W									

University of Texas Medical Branch at Galveston

A PCP-consensus, which is closest in its properties to all the sequences used to calculate it, provides a rational reference for a given virus type. More importantly, it can be combined with experimental data to design single antigens that generate protective antibodies against virus groups with up to 68% diversity.

Danecek P, Lu W, Schein CH. PCP consensus sequences of flaviviruses: correlating variance with vector competence and disease phenotype. J Mol Biol. 2010;396(3):550-63.

Bowen DM, Lewis JA, Lu W, Schein CH. Simplifying complex sequence information: a PCP-consensus protein binds antibodies against all four Dengue serotypes. Vaccine. 2012;30(42):6081-7.

Baker WS, Negi S, Braun W, Schein CH. Producing physicochemical property consensus alphavirus protein antigens for broad spectrum vaccine design. Antiviral Res. 2020;182:104905.

Schein CH, Levine CB, McLellan SLF, Negi SS, Braun W, Dreskin SC, Anaya ES, Schmidt J. Synthetic protein antigens for COVID-19 diagnostics. medRxiv. 2021:2021.02.23.21251934.